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Abstract
Cerebral stroke is a worldwide leading cause of disability. The two-pore domain K+ channels identified as background
channels are involved in many functions in brain under physiological and pathological conditions. We addressed the
hypothesis that TRAAK, a mechano-gated and lipid-sensitive two-pore domain K+ channel, is involved in the
pathophysiology of brain ischemia. We studied the effects of TRAAK deletion on brain morphology and metabolism
under physiological conditions, and during temporary focal cerebral ischemia in Traak2/2 mice using a combination of in
vivo magnetic resonance imaging (MRI) techniques and multinuclear magnetic resonance spectroscopy (MRS) methods. We
provide the first in vivo evidence establishing a link between TRAAK and neurometabolism. Under physiological conditions,
Traak2/2 mice showed a particular metabolic phenotype characterized by higher levels of taurine and myo-inositol than
Traak+/+ mice. Upon ischemia, Traak2/2mice had a smaller infarcted volume, with lower contribution of cellular edema than
Traak+/+ mice. Moreover, brain microcirculation was less damaged, and brain metabolism and pH were preserved. Our
results show that expression of TRAAK strongly influences tissue levels of organic osmolytes. Traak2/2 mice resilience to
cellular edema under ischemia appears related to their physiologically high levels of myo-inositol and of taurine, an
aminoacid involved in the modulation of mitochondrial activity and cell death. The beneficial effects of TRAAK deletion
designate this channel as a promising pharmacological target for the treatment against stroke.
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Introduction
Potassium (K+) channels are involved in many cellular functions
and considered as promising pharmacological targets for the
treatment of neurodegenerative diseases and cerebral stroke, a
worldwide leading cause of disability [1]. The two-pore domain
K+ channels (K2P) allow passive K
+ transmembranous transport
and are involved in cell volume regulation [2]. In the central
nervous system, they participate to neuronal K+ release and spatial
glial K+ buffering [3]. They are designated as the background K+
channels maintaining resting membrane potential and are quasi-
insensitive to classic K+ blockers [2,4,5]. They are viewed as
important targets for modulation of neuronal activity [6]. Despite
common structural features, K2P channels, which are widely
distributed in the central nervous system [7,8,9] and cerebral
arteries [10], show low sequence homology and diverse regulatory
mechanisms [6], including temperature, pH, oxygen tension,
osmolarity and/or membrane stretch [6,11]. Among K2P
channels, TREK channels, which are regulated by neurotrans-
mitters and hormones [2,5], form the first identified lipid- and
stretch-activated K2P channels, with three members TREK-1
(K2P2.1 or KCNK2), TREK-2 (K2P10.1 or KCNK10) and
TRAAK (K2P4.1 or KCNK4) [6]. Because these channels are
activated by potent neuroprotectors such as polyunsaturated fatty
acids (PUFA), it has been suggested that they could all be involved
in neuroprotection [6]. Indeed, activation of TREK-1 channels,
which are located at the pre and post-synaptic levels, by PUFA
leads to a decrease in glutamatergic transmission in models of
brain and spinal chord ischemia, and of epilepsy [12,13].
However, the mechanisms by which PUFA activate TRAAK
would be different from those involved in other TREK channels
[14]. Recently, the implication of TREK-1 has been identified in
several neurological conditions including ischemia [6,12].
TRAAK, the first cloned PUFA- and stretch-activated K2P with
unique functional properties [4], has been found in the human and
the rodent brains [8,9], with an important degree of conservation
between humans and rodents in the cortex [8]. In the mouse
brain, TRAAK mRNA is expressed in the entire hippocampus
[15]. At the cellular level, TRAAK has been localized to neurons
[15], but not to astrocytes [7]. TRAAK displays a specific
electrophysiological behavior. Its current-voltage (I–V) relation-
ship shows an outward rectification that can be approximated by
the Goldman-Hodgkin-Katz current equation predicting specific
curvature of the I–V plot in asymmetric K+ conditions, when
external [K+] is low [16,17]. This result suggests that TRAAK
does not show any voltage sensitivity, a specific feature of
background conductances. TRAAK is opened by membrane
stretch, cell swelling, arachidonic acid [7,18] and closed by
hyperosmolarity [5]. Unlike TREK-1 and TREK-2 channels,
TRAAK is strongly sensitive to internal alkalosis but not to
acidosis, and a synergistic effect between mechanosensitivity and
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alkalosis has been shown [14]. Moreover, whilst Gaq mediated
inhibition of TREK-1 and TREK-2 has been demonstrated [19],
there is only slight inhibition of TRAAK by this pathway [19,20].
The physiological role of TRAAK within the brain is undefined,
and the impact of TRAAK deletion on the cerebral phenotype,
although essential to understanding its function, is unknown.
In vivo magnetic resonance imaging (MRI) and spectroscopy
(MRS) are non-invasive techniques that permit longitudinal
studies of structural, functional and metabolic alterations associ-
ated with brain diseases. They provide the opportunity of
comparative investigations in humans and animals as they
measure the same endpoints to evaluate disease progression.
MRI is considered as the gold standard for identification of
ischemic tissue in stroke, and for differentiation of irreversibly
infarcted core from hypoperfused but salvageable penumbra [21].
Furthermore, the association of MRI to MRS, a technique
enabling the study of cellular metabolism, appears more predictive
of stroke outcome than MRI alone [22,23].
We have undertaken a study dissecting the effects of TRAAK
deletion on brain using in vivo brain MRI and multinuclear MRS,
which may help elucidating connections between genes and
metabolic phenotypes in transgenic mice [24]. We addressed the
hypothesis that TRAAK is involved in the pathophysiology of
brain ischemia by studying a model of transient occlusion of the
middle cerebral artery (tMCAO) [6,12]. Our results demonstrate
that TRAAK strongly influences tissue levels of brain myo-inositol
(myo-Ins) and taurine, and that TRAAK deletion reveals protective
against ischemic injury. This beneficial effect designates this
channel as a pharmacological target for the treatment against
stroke.
Materials and Methods
Animals
Male C57Bl/6J mice (Charles River, L’Arbresle, France) were
used as controls (Traak+/+ mice). Traak2/2 mice were a gift of the
Institut de Pharmacologie Mole´culaire et Cellulaire (IPMC, UMR
7275 CNRS, Valbonne, France). Traak2/2 mice were engineered
as described previously [12]. Briefly, TRAAK genomic clones
were isolated from a 129 mouse genomic BAC library by using a
TRAAK cDNA probe. These clones were then subcloned into the
pBluescript SK (Stratagene). After gene sequencing and mapping,
targeting vectors and PCR primers were designed. KCNK4 gene
disruption was obtained with stop codons inserted by an IRES-geo
cassette, allowing interruption of TRAAK mRNA translation.
After selection of the embryonic stem cell (ES) clone and
linearization of the gene-targeting vector, chimeric males were
generated by the injection of the targeted ES cells into C57Bl/6J
blastocysts. These chimeric males were mated with female C57Bl/
6J mice. Southern blot and PCR analysis of tail DNA from pups
were used to assess the germline transmission. Heterozygous
TRAAK-deficient mice were backcrossed with C57Bl/6J congenic
mice over 11 generations. Traak2/2 mice were viable and
healthy. They showed normal development and were fertile. The
study was performed on Traak2/2 and Traak+/+ mice of the
N10F2 backcross generation to C57Bl/6J congenic strain. All
animals were 10–14 weeks old (25–28 g body weight) at the
beginning of the in vivo MRI/MRS protocol.
Ethics Statement
Animal studies were in agreement with the French guidelines
for animal care from the French Ministry for Agriculture (Animal
Rights Division), the European Council Directive 86/609/EEC of
24 November 1986, and approved by our institutional committee
on Ethics in animal research. Surgery and imaging protocols were
performed under gaseous anesthesia.
Induction of focal cerebral ischemia
Focal ischemia was induced in mice anesthetized with 1–2%
isoflurane in 50% O2: 50% N2O by tMCAO following a
procedure previously described [25]. A midline incision was made
at the neck, and the left common and external carotid arteries
were isolated and ligated with a 4-0 silk suture (Ethicon, Brussels,
Belgium). A Yasargil aneurysm clip (BMH31, Aesculap, Tuttlin-
gen, Germany) was temporarily placed on the internal carotid
artery. A 6-0 nylon monofilament (Ethicon), blunted at tip with an
open flame, was introduced through a small incision into the
common carotid artery and 13 mm distal to the carotid
bifurcation for occlusion of the origin of the left MCA
(supplementary Fig. S1). After one hour of ischemia, the thread
was removed to allow reperfusion of the MCA territory [25].
During surgery, rectal temperature was maintained at 3661uC
with a homemade heating pad. Middle cerebral artery occlusion
and reperfusion were assessed by magnetic resonance angiogra-
phy.
In vivo MR protocol
Gaseous anesthesia (2% isoflurane in 50% O2: 50% N2O) was
used for imaging protocols. Mice were explored on a horizontal
Bruker 47/30 AVANCE Biospec MR system operating at 4.7 T
(Bruker, Karlsruhe, Germany) [26]. Traak+/+ and Traak2/2 mice
were explored before tMCAO, during tMCAO, at immediate
reperfusion (Im-RP), at 24 h post reperfusion (24 h-RP), and at
48 h post reperfusion (48 h-RP). After thread removal, each group
of mice was divided into two subgroups, undergoing either the
MRI or the MRS protocol to avoid prolonged anesthesia. The
duration of each of these protocols was 45 minutes.
MRI protocol. Multi-slice axial transverse relaxation T2-
weighted images and diffusion-weighted spin-echo echoplanar
imaging used to map the apparent diffusion coefficient (ADC)
were acquired with parameters already described [26]. Quantita-
tive cerebral blood flow (CBF) maps were obtained from a single
axial slice with a spin labeling technique [26]. Magnetic resonance
angiography was performed on an 11.75 T vertical Bruker
AVANCE 500WB wide-bore MR system [26], with a 3D-gradient
echo time-of-flight sequence [26].
MRS protocol. 1H-MRS brain spectra were obtained with
the point resolved spatially localized spectroscopy (PRESS)
sequence at two times of echo (TE) (16 and 135 ms). At a TE of
135 ms, the number of detectable metabolites is limited (choline-
containing compounds, creatine+phosphocreatine, lactate) but
overlap of metabolite signals is negligible and spectra show
minimal baseline contribution because of the short transverse
relaxation time (T2) of lipids and macromolecules. In addition,
lactate signal may be unambiguously identified because of lipid
signal suppression. However, signal loss resulting from metabolite
transverse relaxation (T2) is considerable and may lead to an
underestimation of metabolite levels. Moreover, J-coupled mod-
ulation may prevent the detection of many metabolites with
multiplet resonance patterns (i.e. myo-inositol, taurine, glutamine
and glutamate). On the contrary, a short TE (i.e.16 ms) affords the
detection of a greater number of metabolites, including those
bearing strongly coupled spin systems (i.e. myo-inositol, taurine,
glutamine and glutamate) due to negligible J-coupled dephasing.
Furthermore, the signal-to-noise ratio is high at short TE due to
minimal T2 weighting, but baseline distortion caused by the
underlying broad signals from macromolecules and lipids is not
negligible [27,28,29].
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Figure 1. Characteristic brain MRI and MRS of Traak+/+ and Traak2/2 mice. (A) Typical axial T2-weighted images from a Traak
+/+ and a
Traak2/2mouse. COR, cortex; H, hippocampus; S, striatum; V, ventricles. (B) Axial, coronal and sagittal maximum intensity projections of a 3D time-of-
flight angiogram of a Traak+/+ and a Traak2/2 mouse. C: caudal; D: dorsal; R rostral; L: left orientations. 1: common carotid artery; 2: internal carotid
artery; 3: external carotid artery; 4: middle cerebral artery; 5: Willis circle; 6: anterior cerebral artery; 7: ophthalmic artery; 8: basilar artery; 9: vertebral
artery. (C) Representative perfusion maps from a Traak+/+ and Traak2/2 mouse. (D) Representative ADC maps from a Traak+/+ and a Traak2/2 mouse.
(E) and (F) Representative cerebral 1H-MRS (TE = 16 ms) from a Traak+/+ and Traak2/2 mouse. (G) and (H) Representative cerebral 1H-MRS
TRAAK Deletion Protects against Ischemia
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e53266
Water signal suppression was achieved using a ‘‘variable power
radiofrequency pulses with optimized relaxation delays’’ (VAPOR)
sequence. A volume of interest (3.53 mm3) was positioned in each
brain hemisphere, comprising the caudate putamen and thalamus.
Whole brain 31P-MRS was performed with a homemade surface
coil (1 cm diameter) tuned to 31P (81 MHz) positioned over the
skull, using a one-pulse sequence [26].
MR data processing
Data were processed under IDL environment (Interactive Data
Language Research System, Boulder, CO).
MRI Data. Brain volumetry was performed using T2-
weighted images. The ADC maps were generated from the 3 sets
of images recorded with increasing diffusion-weighting along
orthogonal directions (ADCx, ADCy, ADCz). The average ADC
was determined from the trace of the diffusion tensor [26]. CBF
maps were calculated as described elsewhere [26]. Regional ADC
and CBF values were evaluated as an average of pixel values in the
cortex and in the caudate putamen+thalamus.
MRS Data. Data processing of 1H-MRS and 31P-MRS
spectra was performed as described earlier [26]. The 1H-MRS
spectra were referenced to creatine (3.04 ppm). The signal
amplitudes stemming from total creatine (tCr = creatine+pho-
sphocreatine), choline-containing compounds (Cho), glutamate+-
glutamine (Glx), lactate, myo-Ins, N-acetylaspartate (NAA) and
taurine were calculated [26]. Results were expressed as ratios of
the relative area of each metabolite signal to the sum of all
metabolite signal areas (S) (S =NAA+tCr+Cho for spectra
recorded at TE=135 ms, S=NAA+tCr+Cho+Glx+myo-Ins+taur-
ine for spectra recorded at TE=16 ms).
31P-MRS chemical shifts were referenced to phosphocreatine
(PCr) (22.45 ppm). The signal amplitudes corresponding to PCr,
inorganic phosphate (Pi), and a, b and c-ATP were calculated.
The chemical shift between Pi and PCr was used to calculate brain
pH using the relationship: pH=pKa+log(d-0.77/3.39-d), where
pKa is 6.8 and d is the measured chemical shift of Pi in ppm
relative to that of 85% phosphoric acid. Results were expressed as
ratios of metabolites (PCr/Pi; b-ATP/Pi; PCr/b-ATP) [26].
Statistical analysis
A non-parametric analysis was performed using the GraphPad
5.0a software (PRISM, La Jolla, CA). Within a same group,
infarcted volumes, ADC values, CBF values and metabolic ratios
were compared between the two hemispheres using the Wilcoxon
test. The comparison of control values with those obtained at
ischemia or reperfusion within each group (Traak+/+ or Traak2/2
mice) was performed using the Mann-Whitney test, as to the
comparison between Traak+/+ and Traak2/2 mice at each time
point. Values are reported as mean 6 SEM. Significance was set
to p,0.05.
Results
Incidence of TRAAK deletion on brain phenotype
Brain morphology (Fig. 1A) was equivalent in Traak+/+ and
Traak2/2 mice . There were no significant volumetric differences
between groups (data not shown). The anatomy of arteries was
identical without any flow disturbance or difference in vessel
architecture (Fig. 1B). CBF values (Fig. 1C) were similar in cortex
(Traak+/+ mice: 2.6760.09 ml g21 min21, n = 13, Traak2/2
mice: 2.7560.22 ml g21 min21, n = 15) and caudate puta-
men+thalamus (Traak+/+ mice: 4.0260.23 ml g21 min21,
n = 13, Traak2/2 mice: 4.0960.29 ml g21 min21, n = 15). ADC
values (Fig. 1D) were similar in cortex (Traak+/+ mice:
8.0360.2661024 mm2 s21, n = 18, Traak2/2 mice: 8.316
0.2461024 mm2 s21, n = 16) and caudate putamen+thalamus
(Traak+/+ mice: 8.7860.7161024 mm2 s21, n = 18, Traak2/2
mice: 8.3660.3161024 mm2 s21, n = 16).
1H-MRS was performed in the left and right hemispheres of
each animal and showed no difference between the two
hemispheres. Consequently, the mean value of each metabolite
ratio was used for comparison between Traak+/+ and Traak2/2
mice (Table 1). At short TE, significantly higher levels of taurine/S
and myo-inositol/S were measured in Traak2/2 mice compared to
Traak+/+ mice (+327% for taurine/S and +246% for myo-inositol/
S) (Figs. 1E–F and Table 1). At long TE, no difference was
observed (Figs. 1G–H and Table 1). 31P-MRS showed similar pH
and energy metabolite levels in Traak+/+ and Traak2/2 mice
(Figs. 1I–J and Table 1).
The infarction volume is smaller in Traak2/2 mice after
tMCAO
The animals were explored before, during and after tMCAO
(Fig. 2A). The surgical procedure was validated by magnetic
resonance angiography (Fig. 2B). In Traak+/+ mice, the ischemic
lesion was visible at Im-RP (Fig. 2C) and extended to the ipsilateral
hemisphere at 24 h-RP, causing an important midline shift
(Figs. 2C–D). Meanwhile, CBF was reduced in both hemispheres
despite MCA reperfusion (Fig. 2E). In Traak2/2 mice, the
ischemic lesion was hardly detectable before 24 h-RP (Figs. 2F–G),
(TE = 135 ms) from a Traak+/+ and Traak2/2 mouse. (I) and (J) Typical brain 31P-MRS spectra from a Traak+/+ and Traak2/2 mouse (PME:
phosphomonoesters). Scale bars = 1 mm.
doi:10.1371/journal.pone.0053266.g001
Table 1. Comparative brain metabolite analysis of Traak+/+
and Traak2/2 mice.
Metabolite ratio Traak+/+ mice Traak2/2 mice Statistics
1H-MRS (TE=16 ms) (n= 11) (n=15)
NAA/S 0.3160.02 0.2760.01
tCr/S 0.2160.01 0.1960.01
Cho/S 0.1360.01 0.1460.01
Glx/S 0.3260.03 0.3160.02
taurine/S 0.01060.003 0.03660.003 p,0.0001
myo-inositol/S 0.02660.004 0.06460.005 p,0.0001
(lipids+lactate)/S 0.3860.03 0.3660.02
1H-MRS (TE=135 ms) (n= 12) (n=15)
NAA/S 0.3360.01 0.3260.01
tCr/S 0.3360.00 0.3260.01
Cho/S 0.3360.01 0.3660.01
lactate/S 0.0860.01 0.0660.01
31P-MRS (n= 10) (n=10)
PCr/b-ATP 2.0660.19 2.1060.28
PCr/Pi 5.4860.38 6.2960.02
b-ATP/Pi 2.9360.41 3.3660.43
pH 7.1260.01 7.1060.02
doi:10.1371/journal.pone.0053266.t001
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although CBF remained low after reperfusion in the ipsilateral
hemisphere (Fig. 2H). The infarction volume (Fig. 2I) was
significantly lower in Traak2/2 mice at Im-RP (Traak+/+ mice:
42.4068.88 mm3, Traak2/2 mice: 8.5762.82 mm3, p,0.05), at
24 h-RP (Traak+/+ mice: 89.01614.68 mm3, Traak2/2 mice:
24.4068.94 mm3, p,0.005), and at 48 h-RP (Traak+/+ mice:
93.17611.67 mm3, Traak2/2 mice: 49.47613.54 mm3, p,0.05).
Brain volumes were not different in Traak+/+ and Traak2/2 mice
(Fig. 2J). However, an expansion of the ipsilateral hemisphere
occurred at the expense of the contralateral hemisphere in
Traak+/+ mice (Figs. 2C, 2K) indicating a crushing of this
structure. This difference was always significant (tMCAO:
p,0.05; Im-RP: p,0.0001; 24 h-RP: p,0.005; 48 h-RP:
p,0.05). Conversely, Traak2/2 mice did not show any variation
in hemisphere volume during the follow-up (Fig. 2K).
Cellular edema is less developed in Traak2/2 mice
Traak+/+ mice presented a marked drop of ADC values upon
occlusion in the ipsilateral caudate putamen+thalamus (tMCAO,
Im-RP, and 24 h-RP: p,0.001; 48 h-RP: p,0.05), when com-
pared to the control values (Figs. 2D and 3A). The ADC value was
lower in the ipsilateral cortex only during tMCAO (p,0.05). The
contralateral structures were not significantly affected during the
follow-up (Fig. 3B). Comparison of the two hemispheres at the
same time points showed that ADC values were lower in the
ipsilateral cortex except for 48 h-RP (tMCAO, Im-RP, and 24 h-
RP: p,0.05) (Figs. 3A–B). From Im-RP, ADC values became
lower in the ipsilateral caudate putamen+thalamus when com-
pared to the contralateral structure at the same time point (Im-RP:
p,0.0001; 24 h-RP and 48 h-RP: p,0.05).
Traak2/2 mice had normal ADC values (Figs. 2G and 3C–D),
apart from a transient decrease in the ipsilateral caudate
putamen+thalamus at tMCAO (p,0.05). However, the compar-
ison of the ipsilateral and contralateral hemispheres revealed that
ADC values were lower in the ipsilateral caudate putamen+tha-
lamus at tMCAO (p,0.05) and in the ipsilateral cortex at 24 h-RP
only (p,0.01).
Brain microcirculation is less damaged in Traak2/2 mice
and recovers more rapidly after tMCAO
Traak+/+ mice showed a dramatic CBF reduction upon
occlusion in both hemispheres, persisting after reperfusion
(Figs. 2E and 3E–F) and remaining lower than normal in the
ipsilateral cortex (tMCAO: p,0.0005; Im-RP: p,0.001; 24 h-RP:
p,0.005; 48 h-RP: p,0.001), and the ipsilateral caudate puta-
men+thalamus (tMCAO: p,0.0005; Im-RP: p,0.01; 24 h-RP:
p,0.005; 48 h-RP: p,0.05). Perfusion of the contralateral
hemisphere was altered during tMCAO and at Im-RP (contralat-
eral cortex: Im-RP: p,0.05; contralateral caudate putamen+tha-
lamus during tMCAO and at Im-RP: p,0.05) but recovered
thereafter. CBF values tended to be lower in the ipsilateral cortex
until 24 h-RP (tMCAO: p,0.01, Im-RP: p=0.0625). At 48 h-RP,
the CBF in the contralateral caudate putamen+thalamus and the
contralateral cortex represented 77% and 80% of the control value
respectively, whereas in the ipsilateral caudate putamen+thalamus
and the ipsilateral cortex it was only 19% and 9% of the normal
value respectively.
Traak2/2 mice presented a drop of CBF during and after
tMCAO in both hemispheres (Figs. 2H and 3G–H). The CBF
value was lower in the ipsilateral cortex during tMCAO, Im-RP
and at 24 h-RP (p,0.005), and in the ipsilateral caudate
putamen+thalamus during tMCAO and Im-RP (p,0.005), and
at 24 h-RP (p,0.0005). In contrast to Traak+/+ mice, ipsilateral
structures recovered at 48 h-RP in Traak2/2 mice. Contralateral
structures showed reduced perfusion during tMCAO and Im-RP
only (contralateral cortex: tMCAO, p,0.05; contralateral caudate
putamen+thalamus during tMCAO and at Im-RP: p,0.05). At
48 h-RP, the CBF in the contralateral caudate putamen+thalamus
and in the contralateral cortex represented 82% and 77% of the
control value respectively, whereas in the ipsilateral caudate
putamen+thalamus and the ipsilateral cortex it was 44% and 33%
of the normal value respectively. These results reveal a better
recovery of the microcirculation in Traak2/2 mice.
Brain metabolic ischemic profiles are different in Traak+/+
and Traak2/2 mice
At short TE, Traak+/+ mice showed a strong increase in myo-
inositol/S in the ipsilateral hemisphere during tMCAO and at Im-
RP (p,0.05), and a swift increase in Glx/S at Im-RP (p=0.05)
associated with a concomitant rise in taurine/S albeit non-
significant. Traak2/2 showed metabolic variations only in the
contralateral hemisphere consisting in an increase in NAA/S at
tMCAO (p,0.05) and a marked reduction in taurine/S at 24 h-
RP (p,0.05) (Fig. 4).
At long TE, Traak+/+ mice showed a decrease in NAA/S in the
contralateral hemisphere at 48 h-RP (p,0.05), a drop in tCr/S in
the ipsilateral hemisphere at Im-RP (p,0.05) (Fig. 4) and a burst of
lactate at Im-RP statistically significant in the ipsilateral hemi-
sphere (p,0.05). Conversely, Traak2/2 mice showed a progres-
sive increase in tCr/S in the ipsilateral hemisphere (tMCAO, Im-
RP, and 24 h-RP: p,0.05) accompanied by a decrease in Cho/S
at 24 h-RP (p,0.05). A non-significant increase in lactate was
observed in the ipsilateral hemisphere only at Im-RP (Fig. 4).
Brain pH and energetic metabolism are preserved in
Traak2/2 mice
During tMCAO and after reperfusion, Traak+/+ mice showed a
strong decrease in brain pH (tMCAO: p,0.005; Im-RP: p,0.05).
A reduction in PCr/Pi was observed at 48-RP in Traak+/+ mice
(p,0.05), and of ATP/Pi, although non-significant. Traak2/2
mice showed a non-significant decrease in PCr/Pi and ATP/Pi,
and no pH fluctuation during the follow-up (Fig. 5).
Discussion
Although the cellular localization, the regulatory mechanisms
and the neuroprotective effects of TREK channels indicate their
involvement in neuroglial coupling [4,6], TRAAK functions in
brain are still unclear. Here, we provide the first in vivo evidence
establishing a link between TRAAK and neurometabolism.
Furthermore, we report that TRAAK deletion is protective
against cerebral transient focal ischemia.
Deletion of TRAAK alters brain levels of taurine and myo-
inositol
The striking feature of Traak2/2 mice compared to Traak+/+
mice is their higher level of taurine and myo-inositol, two important
mediators of neural cell volume regulation [30]. Taurine is an
aminoacid involved in membrane stabilization, neurotransmission,
and neuroprotection [31,32], and modulates the activity of a wide
range of ion channels in brain including some potassium channels
[32,33]. Brain taurine mainly derives from blood flow and hepatic
synthesis, but can be produced by astrocytes [34] and to a lesser
extent by neurons [35]. Taurine specific transporters (TauT) are
heterogeneously distributed across brain regions and among
neural cell populations [36]. Myo-inositol, a polyol present at low
levels in neurons [37] but highly concentrated in astrocytes [38] is
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Figure 2. Structural and functional changes during tMCAO and following reperfusion in Traak+/+ and Traak2/2 mice. (A) In vivo MRI/
MRS protocol. (B) Axial, coronal and sagittal maximum intensity projections of a 3D time-of-flight angiogram of a Traak+/+ and a Traak2/2 mouse
before ischemia, during tMCAO and after reperfusion. The angiograms show an absence of signal in the MCA during ischemia and a flow recovery
after reperfusion in both Traak+/+ and Traak2/2 mice. (C), (D) and E) T2-weighted MRI, ADC maps, and perfusion maps of a Traak
+/+ mouse before
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a major brain osmolyte [39]. Our results highlight an unexpected
control of neuro-glial metabolism by TRAAK affecting two
quantitatively important organic osmolytes. Under physiological
and pathological conditions, cell shrinkage or swelling may occur.
These processes can be counteracted by regulatory volume
increase or decrease through the gain or loss of osmotically active
compounds such as electrolytes (Na+, K+, Cl2) or organic
molecules called ‘‘non-perturbing’’ solutes (myo-inositol, taurine
or betaine) [40,41,42,43]. Whereas large shifts in electrolytes may
affect membrane potential, structural integrity, and compromise
cellular survival, cells are capable to withstand important
variations in non-perturbing osmolytes without any damage
[40,41,42,43]. Our results demonstrate that TRAAK, an effector
in cell volume regulation [2,43], contributes to the control of non-
perturbing osmolytes. The higher levels of taurine and myo-inositol
in Traak2/2 mice presumably relate to changes in intracellular K+
affecting the transport, efflux or synthesis rate of these osmolytes.
Indeed, the expression of genes encoding taurine (TauT) and myo-
inositol (SMIT) transporters is coupled to osmolarity [44] and
ionic strength in neurons and astrocytes [45,46,47]. An increase in
intracellular K+ resulting from TRAAK deletion might lead to
compensatory mechanisms involving other K2P channels such as
TREK-1 and TREK-2 in neurons. In astrocytes, which are
involved in K+ uptake and buffering [3], these compensatory
mechanisms could possibly involve TREK-2, TASK-1, and
TASK-3 that have been identified in these cells [3]. However,
because K2P channels show only weak inward rectification, it is
likely that other channels such as inward rectifier potassium
channels (Kir) or the Na+/K+/Cl2 co-transporter could contribute
to these mechanisms. Another possibility would consist in the
redistribution of other ions such as Na+, and Cl2 in the
intracellular and extracellular compartments in response to the
shift in intracellular K+. To our knowledge, neither the changes in
electrolyte levels, nor the possible compensation mechanisms that
may affect other K2P in neural cells from Traak
2/2 mice have
been examined so far [48]. Our results suggest that TRAAK
deletion may elicit a shift in intracellular K+ influencing the
concentration of taurine in neurons via both import and synthesis
since neurons are capable to activate taurine synthesis under
hypertonic conditions [35]. However, we cannot exclude the
possibility that TRAAK deletion may also impact taurine level in
astrocytes, since neurons import not only hypotaurine, a precursor
of taurine, but also taurine from astrocytes [38,49]. The increase
in myo-inositol could similarly be linked to the shift in intracellular
K+ resulting from TRAAK deletion. Although myo-inositol is
predominantly found in astrocytes, mRNA of the SMIT co-
transporter for myo-inositol has been found in almost all neurons
[50]. This finding suggests that the level of myo-inositol in neurons
may vary in response to changes in tonicity. As for taurine, we
cannot rule out a possible increase in glial myo-inositol as a
consequence of astrocyte involvement in ionic buffering.
Traak2/2 phenotype is protective against cerebral
ischemia
Altogether, the smaller infarct, the modest cellular edema, the
less damaged microcirculation, and the preserved brain energy
indicate that Traak2/2 phenotype is protective against ischemia.
Traak+/+ mice displayed a significant disruption of CBF in the
ipsilateral hemisphere that persisted for 2 days after ischemia,
whereas the contralateral hemisphere recovered after recircula-
tion. Hypoperfusion in the contralateral hemisphere has already
been reported in humans and in animal models of focal ischemia
[51,52]. This phenomenon termed diaschisis would reflect
depressed metabolic and synaptic activity in remote brain regions.
In addition, Traak+/+ mice showed an important decline of ADC
reflecting acute ultrastructural changes such as cytotoxic edema
affecting mostly astrocytes, extracellular compartment restriction,
and neuronal shrinkage [53]. Cytotoxic edema results from anoxic
depolarization after the failure of Na+/K+-ATPases to maintain
membrane potential upon ATP depletion, which leads to an
accumulation of intracellular electrolytes [54]. During ischemia,
Traak+/+ mice showed important depletion of PCr/Pi accompa-
nied by lactate production and marked acidification. Despite a
partial recovery after reperfusion, pH and PCr/Pi markedly
declined at 48 h-RP, probably because of delayed cell death after
reoxygenation due to mitochondrial impairment [55]. Energy
failure and acidification were presumably underestimated, as it
was not possible to isolate the contribution pertaining only to the
lesion when performing 31P-MRS. The pH fall results from
anaerobic lactate production and H+ accumulation [56]. Tissue
acidification is a well-known trigger of neuronal cell death under
ischemia [57]. The decrease of the neuronal marker NAA in
Traak+/+ mice, indicates neuronal damage or loss due to
mitochondrial impairment, energy failure and excitoxicity [56].
Indeed, NAA synthesis is mitochondrial and coupled to glucose
metabolism [58]. Hence, NAA decrease together with the
reduction in tCr/S and PCr/Pi points to a mitochondrial
dysfunction due to oxygen-glucose deprivation [58]. The severity
of the NAA decrease has a prognostic value in experimental and
human cerebral stroke [23,59].
In Traak2/2 mice, diffusion restriction was almost undetectable
during ischemia, and returned to normal after reperfusion. As for
Traak+/+ mice, contralateral hypoperfusion resolving with recir-
culation was observed. There was a total mismatch between MR
angiography, diffusion-weighted MRI and perfusion-weighted
MRI in these mice. Angiography confirmed the occlusion of
MCAO after surgery, and blood recirculation after thread
withdrawal. CBF was significantly reduced during ischemia and
tended to recover after reperfusion, whereas ischemic lesions were
almost undetectable on ADC maps. Interestingly, a similar finding
has been observed in patients diagnosed with minor ischemic
strokes [60,61,62]. This result suggests that the CBF, although
significantly reduced, was still above the critical threshold leading
to non-reversible energy failure. This hypothesis seems corrobo-
rated by the observation of preserved brain energy metabolism
and pH in these mice. Moreover, Traak2/2 mice did not display
the classical pattern of early metabolic alterations elicited by
ischemia, during tMCAO and at reperfusion. Although T2-weighted MRI and ADC map show an extensive lesion in the ipsilateral hemisphere (arrows)
from 24 h-RP on, the lesion was already visible at tMCAO, but at an anatomic level not shown here. Perfusion maps show a strong reduction in CBF
during tMCAO and following reperfusion in both hemispheres. (F), (G) and (H) T2-weighted MRI, ADC and perfusion maps of a Traak
2/2 mouse
before ischemia, during tMCAO and at reperfusion. Note the small lesion on T2-weighted MRI and ADC maps (arrows) and the total mismatch
between ADC and CBF maps. (I) Temporal course of the infarcted volume, (J) of the brain volume, (K) and of the hemisphere volume in both Traak+/+
and Traak2/2 mice. Control: n=26 and 17, tMCAO: n= 10 and 14, Im-RP: n= 9 and 10, 24 h-RP: n=9 and 9, 48 h-RP: n=3 and 6 for Traak+/+ and
Traak2/2 mice respectively. Abbreviations: contra, contralateral; HM, hemisphere; ipsi, ipsilateral.
doi:10.1371/journal.pone.0053266.g002
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Figure 3. Temporal course of ADC and CBF in Traak+/+ and Traak2/2 mice. (A), (C) ADC values in the ipsilateral hemisphere of Traak+/+ and
Traak2/2 mice respectively. (B), (D) CBF values in the ipsilateral hemisphere of Traak+/+ and Traak2/2 mice respectively. (E), (G) ADC values in the
contralateral hemisphere of Traak+/+ and Traak2/2 mice respectively. (F), (H) CBF values in the contralateral hemisphere of Traak+/+ and Traak2/2
mice respectively. ADC maps, control: n=18 and 16, tMCAO: n=13 and 7, Im-RP: n= 10 and 8, 24 h-RP: n= 8 and 12, 48 h-RP: n= 4 and 6 for Traak+/+
and Traak2/2mice respectively. CBF maps, control: n= 13 and 15, tMCAO: n= 6 and 4, Im-RP: n= 6 and 4, 24 h-RP: n= 4 and 7, 48 h-RP: n=3 and 4 for
Traak+/+ and Traak2/2 mice respectively. Abbreviations: contra, contralateral; COR, cortex; CPU, caudate putamen; ipsi, ipsilateral; Thal, thalamus.
doi:10.1371/journal.pone.0053266.g003
Figure 4. Time evolution of major brain metabolites in Traak+/+ and Traak2/2 mice. Brain metabolic ratios as determined by 1H-MRS in
ipsilateral and contralateral caudate putamen+thalamus. TE = 16 ms: control: n= 11 and 15, tMCAO: n= 6 and 7, Im-RP: n= 4 and 6, 24 h-RP: n=6 and
9, 48 h-RP: n= 4 and 3 for Traak+/+ and Traak2/2mice respectively. 1H-MRS TE= 135 ms: control: n= 12 and 15, tMCAO: n= 7 and 6, Im-RP: n= 4 and 6,
24 h-RP: n= 5 and 10, 48 h-RP: n=4 and 3 for Traak+/+ and Traak2/2 mice respectively. Abbreviations: contra, contralateral; HM, hemisphere; ipsi,
ipsilateral.
doi:10.1371/journal.pone.0053266.g004
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ischemia and consisting in an increase in lactate and a decrease of
NAA, creatine and phosphocreatine [23,59,63,64]. Actually, a
reversible increase in NAA/S and tCr/S occurred during
tMCAO, probably reflecting reduced degradation and/or release
of these compounds, since accrued synthesis of NAA and creatine
seems unlikely in a context of glucose and oxygen deprivation.
Traak+/+ and Traak2/2 mice exhibit different osmolyte
profiles in response to cerebral ischemia induced by
tMCAO
In Traak2/2 mice, taurine decreased progressively from
ischemia, as previously reported in mice undergoing short
(10 minutes) tMCAO [59], a finding consistent with an ische-
mia-evoked efflux of taurine, a protective mechanism counteract-
ing excitotoxicity and allowing regulatory volume decrease to
attenuate cellular edema [65]. The released taurine was then
washed-out by the microcirculation after reperfusion. Conversely,
taurine was not decreased in Traak+/+ mice, probably because
microcirculation was too severely impaired to eliminate the extra-
cellular aminoacid. The apparent response of Traak+/+ mice to
ischemia consisted in a significant increase in myo-inositol/S at
tMCAO and reperfusion associated with an increase in Glx/S
reflecting a rise in glutamine due to glutamate detoxification [59].
Elevated myo-inositol has been reported in patients with cerebral
ischemia and attributed to the replacement of electrolytes by myo-
inositol in swollen astrocytes [66]. Another possibility could be
linked to neuronal osmoregulation since SMIT expression is
increased in neurons after focal cerebral ischemia [67].
Traak2/2 mice better resistance to cellular edema appears
related to the physiologically higher levels of myo-inositol and
especially of taurine which also has cytoprotective properties [31].
Taurine protects neural cells from excitotoxicity by preventing the
expression of caspases triggered by ischemia [68,69,70,71,72] and
by reducing extracellular glutamate release evoked by ischemia
[73,74] whereas taurine deficient astrocytes show less efficient cell
volume regulation upon osmotic challenge [75]. In experimental
cerebral ischemia, taurine administration protects microcircula-
tion, enhances ATP level, down-regulates Bax, up-regulates Bcl-
xL, and diminishes caspase-3 mediated apoptosis. This modulation
of mitochondrial activity and cell death concurs to reduce the
infarct volume [70,72,76,77]. Our results on Traak2/2 mice are
consistent with these previous studies demonstrating the neuro-
protective effects of taurine under ischemia.
The high levels of taurine and myo-inositol, the tight regulation
of astrocytic, neuronal and microvascular functions during stroke,
and the better recovery after reperfusion describe an enhanced
protective response pathway of the neurovascular unit to ischemia.
The effects of the deletion of neuronal [7] and vascular [10]
TRAAK channels suggest that TRAAK contributes to the
regulation of organic osmolytes. The observation of a more
important infarct in Traak+/+ mice could be linked to the
morphometric changes and cytoskeleton reorganization accompa-
nying cell swelling under ischemia [78,79]. These modifications
may induce membrane stretching, a process known to activate
TRAAK channels and to increase their sensitivity to arachidonic
acid [14]. TRAAK activation by high concentrations of
arachidonic, as those produced under ischemia, could be highly
detrimental because the opening of the channels would progres-
sively drain K+ out of the neurons [16].
Pharmacological modulation of TRAAK for brain stroke
treatment
Our results are consistent with the hypothesis that TRAAK
inhibition could be neuroprotective under certain conditions [80].
Activation of TRAAK channels would be the expected mechanism
to provide neuroprotection since a-linolenic acid and riluzole, two
non-selective activators of TREK family channels, were found
protective against focal cerebral ischemia [25]. The beneficial
effects observed in C56BL/6J mice induced for tMCAO and
treated with these agents were attributed to the activation of
TREK-1 and TRAAK channels, although they were probably
involving other K+ channels, voltage-dependent Na+ and Ca2+
channels [13]. Indeed, riluzole not only inhibits glutamatergic
pathways, but also blocks voltage-gated K+ channels [81], calcium
channels [82,83], persistent Na+ currents (INa,p) [84] and
modulates brain sodium channel Nav1.1 under acute cerebral
ischemia [85]. In addition, a-linolenic acid can bind to voltage
sensitive Na+ channels [86]. The precise contribution of TRAAK
channels activation to the protective effects observed under focal
ischemia was undetermined. On the other hand, sipatrigine, a
neuroprotective agent and potent inhibitor of TREK-1 and
TRAAK channels [80] was found neuroprotective under focal and
global ischemia [87]. In addition to its action on TREK-1 and
TRAAK channels, sipatrigine blocks sodium channels including
INa,p, and voltage-gated Ca
2+ channels, and inhibits glutamate
release [88]. Although an important limitation of these pharma-
cological approaches is the use of non-selective activators or
inhibitors, these studies lead to the apparently contradictory
conclusion that neuroprotection mediated by TREK channels
could be achieved via both activation and inhibition. Our findings
Figure 5. Time evolution of brain energy metabolites and pH determined by 31P-MRS of the whole brain. Control: n= 10 and 10,
tMCAO: n=10 and 7, Im-RP: n= 4 and 4, 24 h-RP: n=5 and 3, 48 h-RP: n=3 and 3 for Traak+/+ and Traak2/2 mice respectively.
doi:10.1371/journal.pone.0053266.g005
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on mice lacking TRAAK indicate that specific blockade of this
channel could represent a strategy to confer neuroprotection
under ischemia. Since increased brain taurine appears as one the
main positive consequences of TRAAK deletion, the administra-
tion of this aminoacid should theoretically reproduce, at least in
part, the neuroprotective effects observed upon ischemia in mice
lacking TRAAK. Because administration of taurine failed to
significantly increase the level of this aminoacid in the human
brain [31], we suggest that the cerebroprotective effects resulting
from TRAAK deletion should prompt the search for selective
blockers of TRAAK [89] for preventive or therapeutic treatments
against stroke
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